Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
MOUNTAIN VIEW, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) (IGM) today announced the closing of its upsized underwritten public offering of 1,221,224 shares of its...
-
MOUNTAIN VIEW, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) (IGM) today announced the pricing of its upsized underwritten public offering of shares of its common...
-
MOUNTAIN VIEW, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell $150 million of shares of its common stock and, in...
-
- 9 of 14 Patients Showed Reduction in Tumor Size, Including Two Recently Reported Complete Responses - - Company to Host Conference Call and Webcast Today at 2:00 p.m. ET - MOUNTAIN VIEW,...
-
MOUNTAIN VIEW, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
-
MOUNTAIN VIEW, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
-
MOUNTAIN VIEW, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
-
MOUNTAIN VIEW, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- - Initial Data from Phase 1 Trial of IGM-2323 in Relapsed/refractory Non-Hodgkin’s Lymphoma to be Presented at the 62nd American Society of...
-
MOUNTAIN VIEW, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
-
MOUNTAIN VIEW, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...